Tucatinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 50 mg, 150 mg
Reference Brands: Tukysa (USA, EU/UK), Tukavo (India)
Category:
Oncology Cancer Care
Tucatinib is available in Tablets
and strengths such as 50 mg, 150 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tucatinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tucatinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tucatinib is an oral anticancer medication used in the treatment of HER2-positive cancers, particularly advanced or metastatic breast cancer. It is a small-molecule inhibitor that selectively targets the human epidermal growth factor receptor 2 (HER2), a protein that promotes the growth of certain cancer cells. By blocking HER2 signaling pathways, tucatinib helps slow down tumor growth and reduce the spread of cancer. This targeted mechanism allows it to work effectively while minimizing effects on other receptors compared to some older therapies.
Tucatinib is commonly used in combination with other anticancer medicines such as trastuzumab and capecitabine to improve treatment outcomes in patients who have previously received other HER2-directed therapies. One of the important advantages of tucatinib is its ability to provide benefits for patients whose cancer has spread to the brain, a condition that can be difficult to treat with many standard therapies. The medicine is administered orally in tablet form, making it convenient for ongoing treatment.
Overall, tucatinib represents an important advancement in targeted oncology therapy, offering an additional option for managing HER2-positive cancers and improving disease control in patients with advanced stages of the disease.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing